Transgene SA has nominated Maria Landel and Maya Said as independent directors to help guide its work on candidate vaccines for the treatment of cancer and infectious diseases. Subject to the approval of shareholders on 8 June, the Transgene board will have 10 members, the majority of whom will be independent directors. Ms Landel is the founder of Marie Landel & Associates, now Axcelia Partners, which is a Cambridge, Massachusetts consultancy that advises European companies on setting up US subsidiaries. She is also a Chevalier de la Légion d’Honneur and has previously served as a foreign trade advisor to the French government.
Dr Said is a previous head of oncology policy and market access at Novartis and before that, head of strategy and global R&D at Sanofi SA. She holds a doctorate in electrical engineering, computer science and systems biology from the Massachusetts Institute of Technology, US and has authored over 20 scientific papers.
Transgene announced the nominations on 19 April 2017.
Copyright 2017 Evernow Publishing Ltd